177 Lu-PSMA Thearpy

Conclusion: The use of 177 Lu-PSMA therapy demonstrates lowered PSA and pain levels in metastatic castration resistant prostate cancer patient’s who have not responded or no longer responds to chemotherapy or hormone treatments. The positive outcome sustained with the use of 177-Lu used in cancer therapy is credited to the radiopharmaceutical’s longer half-life of 6.7 days combined with PSMA naturally encoded in the human gene. With the development of 177 Lu-PSMA, studies have shown promising results of overall improvement in quality of life for metastatic castration resistant prostate cancer patients. The potential effectiveness observed with multiple treatments in aggressive forms of prostate cancer with use of 177 Lu-PSMA have minimized the spread of advanced cancer to the rest of the body and have even shown complete remission of the cancer.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Technologist Student Papers I Source Type: research